Prevnar 13

03 February 2015

The Advisory Committee on Immunization Practices (ACIP) has revised the pneumococcal vaccination guidelines to recommend Prevnar 13® for adults aged 65+. The official revised ACIP recommendations have been published in the Morbidity and Mortality Weekly Report (MMWR).

The ACIP now recommends Prevnar 13® for both pneumococcal vaccine-naive and PPSV23–previously vaccinated adults aged 65+

 

Pneumococcal Vaccine-naïve Adults age ≥ 65 years

(Pneumococcal vaccine naive or unknown vaccine history.)

Administer Prevnar 13 first

Administer PPSV23 6 to 12 months later (If not possible in that time window, then during the next appointment)

 

Adults previously vaccinated with PPSV23 at age ≥ 65

Administer Prevnar 13 (At least 1 year after the most recent dose of PPSV23)

 

Adults previously vaccinated with PPSV23 at age before 65 years but are now 65 years

Administer Prevnar 13 (At least 1 year after the most recent dose of PPSV23)

Administer PPSV23 6 to 12 months later (No sooner than 5 yrs. after the most recent dose of PPSV23)

 

IMPORTANT PRESCRIBING INFORMATION FOR PREVNAR 13®

  • Effectiveness when administered <5 years after pneumococcal polysaccharide vaccine is not known
  • Antibody responses to Prevnar 13® were lower in persons ≥65 years of age compared to antibody responses in persons 50 through 59 years of age
    INDICATIONS
  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
  • PPSV23= 23-valrnt pneumococcal polysaccharide vaccine.
  • In adults 50 years and older for pneumococcal pneumonia and invasive disease. Indication is based on immune responses
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)
    Limitations of Use and Effectiveness
  • Prevnar 13® will only help protect against S pneumoniae serotypes in the vaccine
  • Effectiveness when administered <5 years after pneumococcal polysaccharide vaccine is not known
    IMPORTANT SAFETY INFORMATION
  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • In adults, antibody responses to Prevnar 13® were diminished when given with inactivated Influenza Virus Vaccine
  • In adults, the commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle or joint pain, decreased appetite, chills, or rash
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status, and the potential benefits and risks
  • In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
  • In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
    Please see full Prescribing Information for Prevnar 13®.
    Reference: 1. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014; 63(37):822-825.